Objective: To determine human papillomavirus (HPV) vaccine acceptance among parents of 10- to 15-year-old adolescents.
Materials And Methods: Five hundred seventy-five parents or guardians completed a 30-question survey regarding their knowledge of HPV and acceptance of an HPV vaccine. Afterward, subjects read an HPV educational fact sheet and completed a 26-question survey. Results were compared using the chi test, analysis of variance, and McNemar's test.
Results: More than 60% of subjects had a general understanding of HPV. Parents opposed to the HPV vaccine were more likely to believe it would promote earlier initiation of coitus compared with parents supportive or undecided about vaccination (24%, 9%, and 6%, respectively; p = .003). Of the subjects initially opposed to or undecided about the HPV vaccine, 37% and 65%, respectively, supported HPV vaccination after an educational intervention.
Conclusions: A brief educational intervention significantly improved parent's acceptance of the HPV vaccine. The negative impact of an HPV vaccine perceived as condoning early initiation of sexual intercourse seems to be minimal.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00128360-200407000-00005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Focus Groups With Guatemalan Community Leaders About Barriers to Cervical Cancer Prevention and Control.
Health Promot Pract
January 2025
The University of Utah College of Nursing, Salt Lake City, UT, USA.
Cervical cancer is the leading cause of cancer-related death among Latin American women, including Guatemalans. This is troubling, given we have a vaccine, screening tool, and treatment for this preventable disease. Human papillomavirus (HPV) causes most cervical cancer.
View Article and Find Full Text PDFFirst Report of HPV Genotyping and Distribution in People Living with and Without HIV from Iran and the Middle East.
Curr HIV Res
January 2025
Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Aims: In people living with human immune deficiency (PLHIV), the rates of human papillomavirus (HPV) infection, mixed types, and high-risk (HR) strains increase, while the virus clearance is prevented. Here, we report HPV genotyping in PLHIVs from Iran and the Middle East region for the first time.
Methods: HPV genotyping in referring individuals from different provinces to our laboratory was evaluated over 2023-2024.
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies.
Hum Vaccin Immunother
December 2025
Merck & Co, Inc, Rahway, NJ, USA.
Post hoc analyses of 9-valent human papillomavirus (9vHPV) vaccine immunogenicity were conducted in five Phase 3 studies that enrolled males. Month 7 antibody geometric mean titers (GMTs) after three 9vHPV vaccine doses were analyzed in 10,024 males/females aged 16-26 years from studies 001 (NCT00543543), 002 (NCT00943722), 003 (NCT01651949), and 020 (NCT02114385). Covariates considered were age, gender, sexual orientation, region of residence, and race.
View Article and Find Full Text PDFHuman Papillomavirus Vaccination in Adult Survivors of Childhood, Adolescent, and Young Adult Cancers: A Missed Opportunity.
Cureus
December 2024
Otolaryngology and Public Health Sciences, Henry Ford Health System, Detroit, USA.
Introduction Studies assessing human papillomavirus (HPV) vaccination uptake in survivors of childhood, adolescent, and young adult (CAYA) cancers are sparse. We examined HPV vaccine uptake between survivors of CAYA cancer aged 18-35 and 18-35-year-old respondents without a cancer diagnosis in the United States. Methods We used the 2017-2018 National Health Interview Survey, a national, annual cross-sectional national dataset that monitors health-related information on the non-institutionalized civilian population in the United States.
View Article and Find Full Text PDFA Qualitative Study of Attitudes Toward HPV Vaccine Recommendation in Otolaryngology Clinics.
Laryngoscope Investig Otolaryngol
February 2025
Objective: The incidence of human papillomavirus (HPV)-related oropharyngeal cancers has increased such that they are now the most prevalent HPV-related cancer. In 2020, the Food and Drug Administration (FDA) expanded the indication for Gardasil-9 to include the prevention of oropharyngeal and other head and neck cancers caused by selected HPV types, but uptake remains low. Otolaryngology office interactions may provide opportunities to increase uptake, given the relevance of HPV to clinical practice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!